CN110709393A - Ldha活性抑制剂 - Google Patents

Ldha活性抑制剂 Download PDF

Info

Publication number
CN110709393A
CN110709393A CN201880034909.5A CN201880034909A CN110709393A CN 110709393 A CN110709393 A CN 110709393A CN 201880034909 A CN201880034909 A CN 201880034909A CN 110709393 A CN110709393 A CN 110709393A
Authority
CN
China
Prior art keywords
thiophen
alkyl
group
thio
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880034909.5A
Other languages
English (en)
Chinese (zh)
Inventor
乔·克拉韦内斯
B·西恩
S·朗德沃尔
C·A·博恩
K·妮达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actec Pharmaceutical Co Ltd
Original Assignee
Actec Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actec Pharmaceutical Co Ltd filed Critical Actec Pharmaceutical Co Ltd
Publication of CN110709393A publication Critical patent/CN110709393A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201880034909.5A 2017-05-16 2018-05-16 Ldha活性抑制剂 Pending CN110709393A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1707856.9A GB201707856D0 (en) 2017-05-16 2017-05-16 Compounds
GB1707856.9 2017-05-16
PCT/GB2018/051333 WO2018211277A1 (en) 2017-05-16 2018-05-16 Ldha activity inhibitors

Publications (1)

Publication Number Publication Date
CN110709393A true CN110709393A (zh) 2020-01-17

Family

ID=59201440

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034909.5A Pending CN110709393A (zh) 2017-05-16 2018-05-16 Ldha活性抑制剂

Country Status (7)

Country Link
US (1) US11142520B2 (enExample)
EP (1) EP3625225B1 (enExample)
JP (1) JP2020520388A (enExample)
CN (1) CN110709393A (enExample)
ES (1) ES2923652T3 (enExample)
GB (1) GB201707856D0 (enExample)
WO (1) WO2018211277A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450399A (zh) * 2019-05-02 2022-05-06 卢万天主教大学 用于治疗癌症的乳酸脱氢酶抑制剂多肽
WO2025011479A1 (en) * 2023-07-13 2025-01-16 Meta Pharmaceuticals (Hk) Limited Pyrazole based inhibitors of LDH and their use in immune and inflammatory diseases

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230346862A1 (en) 2022-05-02 2023-11-02 Athanor Biosciences, Inc. Cancer eradicating - bio-nanoparticles (ce-bnp)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015140133A1 (en) * 2014-03-17 2015-09-24 F. Hoffmann-La Roche Ag Piperidine-dione derivatives
WO2015142903A2 (en) * 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
WO2017055396A1 (en) * 2015-09-30 2017-04-06 Selvita S.A. Pyrazolidine derivatives and related compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430671T2 (de) 1993-11-19 2002-11-21 Parke, Davis & Company 5,6-dihydropyron derivate als protease inhibitoren und antivirusmitteln
US5789440A (en) * 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
GB201707852D0 (en) * 2017-05-16 2017-06-28 Arctic Pharma As Compounds
GB201707846D0 (en) * 2017-05-16 2017-06-28 Spermatech As Use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015140133A1 (en) * 2014-03-17 2015-09-24 F. Hoffmann-La Roche Ag Piperidine-dione derivatives
WO2015142903A2 (en) * 2014-03-17 2015-09-24 Genentech, Inc. Method of controlling lactate production with piperdine-dione derivatives
WO2017055396A1 (en) * 2015-09-30 2017-04-06 Selvita S.A. Pyrazolidine derivatives and related compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FAUBER BP, ET AL.: "Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450399A (zh) * 2019-05-02 2022-05-06 卢万天主教大学 用于治疗癌症的乳酸脱氢酶抑制剂多肽
WO2025011479A1 (en) * 2023-07-13 2025-01-16 Meta Pharmaceuticals (Hk) Limited Pyrazole based inhibitors of LDH and their use in immune and inflammatory diseases

Also Published As

Publication number Publication date
US11142520B2 (en) 2021-10-12
ES2923652T3 (es) 2022-09-29
EP3625225B1 (en) 2022-06-29
US20200165233A1 (en) 2020-05-28
WO2018211277A1 (en) 2018-11-22
GB201707856D0 (en) 2017-06-28
EP3625225A1 (en) 2020-03-25
JP2020520388A (ja) 2020-07-09

Similar Documents

Publication Publication Date Title
JP6980734B2 (ja) 心臓状態に対するピリミジンジオン化合物
JP5592388B2 (ja) 疼痛治療用のｐ２ｘ３受容体アンタゴニスト技術分野
KR102872871B1 (ko) 모발 성장을 조절하기 위한 조성물 및 방법
EP2435407B1 (en) Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
EP2842955B1 (en) Trk-inhibiting compound
AU2019250163A1 (en) Compositions and methods of modulating 15-PGDH activity
EA018150B1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
EP3083622B1 (en) Maleimide derivatives as modulators of wnt pathway
JP2021054856A (ja) トリアジン化合物及びその医薬用途
WO2022017444A1 (zh) Shp2抑制剂及其组合物和应用
EA007063B1 (ru) ПРОИЗВОДНЫЕ АМИНОБЕНЗАМИДОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ГЛИКОГЕНСИНТАЗА-КИНАЗЫ 3β;
CN101959404A (zh) 单磷酸腺苷活化蛋白激酶调节剂
JP2021503013A (ja) Ａｃｓｓ２阻害剤およびその使用方法
JPWO2012039371A1 (ja) シクロプロパン化合物
EP2383263A2 (en) Novel thiazolidinedione derivative and use thereof
EP3010903A1 (en) Olefin substituted oxindoles having ampk activity
AU2017290233A1 (en) 1 H-pyrazol-1 -YL-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof
TW202003472A (zh) 鈣蛋白酶(calpain)調節劑及其醫療用途
CN112189012A (zh) 作为pi3激酶和自噬途径的调节剂的三取代芳基和杂芳基衍生物
CN110709393A (zh) Ldha活性抑制剂
BR112016005606B1 (pt) Composto, composição farmacêutica, e usos de um composto
CN101289444B (zh) 一种嘧啶衍生物及其医药用途
CN115916762A (zh) 调节17β-羟基类固醇脱氢酶13型的化合物和方法
JP2025525344A (ja) Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド
KR20100137090A (ko) 신규한 티아졸리딘디온 유도체 및 그의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200117

WD01 Invention patent application deemed withdrawn after publication